BeiGene Ltd.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2010-01-01
- Employees
- 10K
- Market Cap
- $22.1B
- Website
- http://www.beigene.com
Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-05-08
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 224
- Registration Number
- NCT03519230
- Locations
- 🇨🇳
Anhui Provincial Cancer Hospital, Hefei, Anhui, China
🇨🇳Peking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳Henan Cancer Hospital, Zhengzhou, Henan, China
Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms
- Conditions
- Extranodal NK/T-cell Lymphoma, Nasal TypeAngioimmunoblastic T-Cell Lymphoma RecurrentAngioimmunoblastic T-Cell Lymphoma RefractoryPeripheral T-Cell Lymphoma RefractoryAnaplastic Large Cell Lymphoma, ALK-PositiveAnaplastic Large Cell Lymphoma, ALK-negativePeripheral T Cell LymphomaAdult Nasal Type Extranodal NK/T-cell LymphomaPTCLExtranodal NK/T-cell Lymphoma
- Interventions
- First Posted Date
- 2018-04-10
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 77
- Registration Number
- NCT03493451
- Locations
- 🇨🇦
British Columbia Cancer Agency the Vancouver Centre, Vancouver, British Columbia, Canada
🇨🇳Sun Yat Sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Carcinoma
- First Posted Date
- 2018-03-19
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 30
- Registration Number
- NCT03469557
- Locations
- 🇨🇳
Fifth Medical Center of Pla General Hospital, Beijing, Beijing, China
🇨🇳Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
🇨🇳Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China
Safety and Pharmacokinetics of Zanubrutinib (BGB-3111) in Healthy Subjects and Those With Impaired Liver Function
- First Posted Date
- 2018-03-14
- Last Posted Date
- 2020-04-24
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 29
- Registration Number
- NCT03465059
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
A Two-Part Phase 1 Study to Investigate the Safety and Tolerability of Supratherapeutic Dose of Zanubrutinib and Effect of Zanubrutinib on Cardiac Repolarization in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2018-02-14
- Last Posted Date
- 2020-04-24
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 40
- Registration Number
- NCT03432884
- Locations
- 🇺🇸
Frontage Clinical Services, Inc., Secaucus, New Jersey, United States
Anti-PD-1 in Combination With Chemotherapy as First-Line Treatment to Lung Cancer
- First Posted Date
- 2018-02-14
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 54
- Registration Number
- NCT03432598
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Beijing Chest Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳Jiangsu Province Hospital, Nanjing, Jiangsu, China
A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2018-02-13
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 512
- Registration Number
- NCT03430843
- Locations
- 🇧🇪
UZ Antwerpen, Antwerp, Belgium
🇨🇳Anhui Medical University - The Second Hospital, Hefei, Anhui, China
🇨🇳The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China
Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-02-09
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 136
- Registration Number
- NCT03427814
- Locations
- 🇺🇸
Scri Florida Cancer Specialist East, West Palm Beach, Florida, United States
🇺🇸Goshen Center For Cancer Care, Goshen, Indiana, United States
🇺🇸Novant Health Hematology Charlotte, Charlotte, North Carolina, United States
Study of BGB-A317 in Participants With Previously Treated Unresectable HCC
- First Posted Date
- 2018-02-05
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 249
- Registration Number
- NCT03419897
- Locations
- 🇨🇳
The Second Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳Military Hospital of China, Beijing, Beijing, China
🇨🇳Chinese Pla General Hospital, Beijing, Beijing, China
Phase 3 Study of Tislelizumab Versus Sorafenib in Participants With Unresectable HCC
- Conditions
- Interventions
- First Posted Date
- 2018-01-26
- Last Posted Date
- 2024-01-10
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 674
- Registration Number
- NCT03412773
- Locations
- 🇺🇸
University of California - Hematology and Oncology, Los Angeles, California, United States
🇺🇸Cancer Treatment Centers of America - Oncology, Philadelphia, Pennsylvania, United States
🇺🇸UMass Memorial Medical Center, Worcester, Massachusetts, United States